

## Concurrent cisplatin and 5-fluorouracil *versus* concurrent cisplatin and docetaxel with radiotherapy for esophageal squamous cell carcinoma: a propensity score-matched analysis

### Supplementary Material

**Supplementary Table S1: Literature overview of clinical trials concerning PF or DP in definite chemoradiotherapy for esophageal cancer.**

Author	No	Histology	Chemotherapy	Radiotherapy	Response	Survival	Toxicitygr 3-4	
[Reference]							Hematological	Non-hematological
Cooper [4]	61	SCC:51 ADC:10	Cisplatin 75 mg/m <sup>2</sup> and 5-Fu 1g/m <sup>2</sup>	50Gy/25f	By follow-up Complete: 27%, Persistent:26%	5-year OS: 26%		
Minsky [11]	218	SCC:187 ADC:31	5-Fu 1g/m <sup>2</sup> for4 days and cisplatin 75 mg/m <sup>2</sup>	A: 64.8Gy B: 50.4Gy		2-year OS: A: 31%; B: 40%	A: 73 (67%); B: 75 (69%)	
Ishida [5]	60	SCC	Cisplatin 70 mg/m <sup>2</sup> on days 1, 29 and5-FU 700 mg/m <sup>2</sup> /day on days 1–4 , 29–32	60Gy/30f	CR: 9 (15.0%) PR: 32 (53.3%)	2-year OS: 31.5%	Leukocyte: 20; Hemoglobin: 4; Platelet:3; Neutrophil: 5	Esophagitis:2; ALT:6; Nausea:3; Infection:1; Dyspnea:2
Bedenne [12]	142	SCC:124 ADC:18	5-FU 800 mg/m <sup>2</sup> /day on Days 1-5 and Cisplatin15 mg/m <sup>2</sup> on Days 1-5 for 5 cycles	66Gy/33f or 45 Gy/15f		2-year OS: 36.5%	Leukocytes :26; Febrile neutropenia:3; Hemoglobin:3; Thrombocytes:9	Vomiting:9; Esophagitis:5; Cardiovascular:2; Stomatitis:1
Kato [13]	76	SCC	5-FU 400 mg/m <sup>2</sup> /day on Days 1-5 and 8-12,	60Gy/30f	CR: 46 (62.2%)	3- 5- year OS:44.7%		Esophagitis :17%;

			and Cisplatin 40 mg/m <sup>2</sup> on Days 1 and 8 every 5 weeks			and 36.8%		Nausea :17% ; Hyponatremia :16% ; Infection without neutropenia:12%
Nishimura [14]	91	SCC:90 ADE:1	A:cisplatin 70 mg/m <sup>2</sup> Days 1 and 29 and 5-FU 700 mg/m <sup>2</sup> Days 1–5 and 29–33 B:cisplatin 7 mg/m <sup>2</sup> Days 1–5, 8–12, 29–33 and 36–40, and 5-FU 250 mg/m <sup>2</sup> Days 1–14 and 29–42	60Gy/30f		A: 2- and 5-year OS: 46% and 35% B: 2- and 5-year OS:44% and 22%		
Conroy [15]	133	SCC: 115 ADC:18	5-Fu 1000 mg/m <sup>2</sup> for 4 days and cisplatin 75 mg/m <sup>2</sup>	50Gy / 25f	CR: 55 (43%) PR: 28 (22%)	Median OS: 17.5m; median PFS:9.4m	Anaemia: 14; Thrombocytopenia:10 ; Lymphopenia:22; Neutropenia: 37; Febrile neutropenia:9	Dysphagia:31; Asthenia:13;Oesophagitis :11;
Li [9]	59	SCC	docetaxel 60 mg/m <sup>2</sup> ; cisplatin 80 mg/m <sup>2</sup> for 2 cycles every three weeks	50–64 Gy / 25–35 f	CR: 71.2% PR: 27.1%	3-year OS: 36.7%	Leukocytopenia:24; Neutropenia: 32; Anemia:1; Thrombocytopenia:5	Esophagitis:5; Pleural effusion: 4; Cough: 2; Liver function:1
Day [25]	24	SCC : 11 ADE : 13	docetaxel 15–30 mg/m <sup>2</sup> and cisplatin 15–30 mg/m <sup>2</sup> per week	50Gy / 25f	CR: 33% PR: 17%	5-year OS: 30.5% 5-year PFS: 26.5%	4 (16.6%)	Dysphagia: 9; Nausea: 3 Fatigue: 4; Feve: 1 Constipation:3
Zhao [17]	90	SCC	DP (n=45): docetaxel 75mg/m <sup>2</sup> and cisplatin 75mg/m <sup>2</sup> every 28 days; PF (n=45): 5-FU at days 1–4 (250 mg/m <sup>2</sup> /day), and cisplatin (75 mg/m <sup>2</sup> ) every	50.4Gy / 28f	DP: CR: 40% PR: 33.3% ; PF: CR: 28.9% PR: 24.4%	DP:median OS: 43.2m; median PFS: 25.3m; PF:median	DP: 16(35.6%); PF:11 (24.4%)	DP: Esophagitis: 8; Pneumonia:3; Mucositis:1; PF: Esophagitis:

			28 days			OS:22.3m;median PFS:14.0m		9;Pneumonia:2; Mucositis:1;
--	--	--	---------	--	--	------------------------------	--	--------------------------------

*Abbreviations:* DP: docetaxel and cisplatin; PF: cisplatin and fluorouracil; SCC: squamous cell carcinoma; ADE: adenocarcinoma; Fu:fluorouracil; OS: overall survival; PFS: progression-free survival.